332 related articles for article (PubMed ID: 25761299)
1. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
Hoorn EJ
Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
[TBL] [Abstract][Full Text] [Related]
2. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
3. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
4. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
5. Advances in treatment of hyperkalemia in chronic kidney disease.
Sarafidis PA; Georgianos PI; Bakris GL
Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
[TBL] [Abstract][Full Text] [Related]
6. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR; Bakris GL; Bushinsky DA; Mayo MR; Garza D; Stasiv Y; Wittes J; Christ-Schmidt H; Berman L; Pitt B;
N Engl J Med; 2015 Jan; 372(3):211-21. PubMed ID: 25415805
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
8. Potassium binding for conservative and preservative management of chronic kidney disease.
Clegg DJ; Palmer BF
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):29-38. PubMed ID: 31714287
[TBL] [Abstract][Full Text] [Related]
9. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
10. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to management of hyperkalaemia in kidney transplantation.
Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K
Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094
[TBL] [Abstract][Full Text] [Related]
12. Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
Georgianos PI; Agarwal R
Kidney Int; 2018 Feb; 93(2):325-334. PubMed ID: 29276100
[TBL] [Abstract][Full Text] [Related]
13. New therapies for hyperkalemia.
Leon SJ; Harasemiw O; Tangri N
Curr Opin Nephrol Hypertens; 2019 May; 28(3):238-244. PubMed ID: 30865167
[TBL] [Abstract][Full Text] [Related]
14. [Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].
De Stefano T; Borrelli S; Garofalo C; Provenzano M; De Nicola L; Minutolo R; Conte G
G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234232
[TBL] [Abstract][Full Text] [Related]
15. New drugs to prevent and treat hyperkalemia.
Lepage L; Desforges K; Lafrance JP
Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
[TBL] [Abstract][Full Text] [Related]
16. Patiromer: A Review in Hyperkalaemia.
Blair HA
Clin Drug Investig; 2018 Aug; 38(8):785-794. PubMed ID: 30030701
[TBL] [Abstract][Full Text] [Related]
17. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
18. New potassium binders reduce the risk of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors.
Tamargo M; Tamargo J
Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):193-194. PubMed ID: 29982385
[No Abstract] [Full Text] [Related]
19. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
[TBL] [Abstract][Full Text] [Related]
20. Managing Hyperkalemia: Stepping Into a New Frontier.
Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]